Published in AIDS Weekly, October 30th, 2000
"The optimal management of people who have HIV infection with a nascent low viral burden and high CD4 count is controversial," stated A.M. Bayoumi and colleagues from the University of Toronto, Ontario, and Stanford University, California. "Empirical evidence for a survival benefit from early therapy is scant whereas toxicity from early therapy may be considerable. We used a decision model to compare the health effects and costs of early and delayed treatment strategies."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.